515 related articles for article (PubMed ID: 34479848)
1. An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment.
Fuzimoto AD
J Integr Med; 2021 Sep; 19(5):375-388. PubMed ID: 34479848
[TBL] [Abstract][Full Text] [Related]
2. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants.
Nair MS; Huang Y; Fidock DA; Polyak SJ; Wagoner J; Towler MJ; Weathers PJ
J Ethnopharmacol; 2021 Jun; 274():114016. PubMed ID: 33716085
[TBL] [Abstract][Full Text] [Related]
3.
Agrawal PK; Agrawal C; Blunden G
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744958
[TBL] [Abstract][Full Text] [Related]
4. Instant determination of the artemisinin from various Artemisia annua L. extracts by LC-ESI-MS/MS and their in-silico modelling and in vitro antiviral activity studies against SARS-CoV-2.
Dogan K; Erol E; Didem Orhan M; Degirmenci Z; Kan T; Gungor A; Yasa B; Avsar T; Cetin Y; Durdagi S; Guzel M
Phytochem Anal; 2022 Mar; 33(2):303-319. PubMed ID: 34585460
[TBL] [Abstract][Full Text] [Related]
5. Network pharmacology-based predictions of active components and pharmacological mechanisms of Artemisia annua L. for the treatment of the novel Corona virus disease 2019 (COVID-19).
Tang Y; Li X; Yuan Y; Zhang H; Zou Y; Xu Z; Xu Q; Song J; Deng C; Wang Q
BMC Complement Med Ther; 2022 Mar; 22(1):56. PubMed ID: 35241045
[TBL] [Abstract][Full Text] [Related]
6. Virtual Screening of
Miandad K; Ullah A; Bashir K; Khan S; Abideen SA; Shaker B; Alharbi M; Alshammari A; Ali M; Haleem A; Ahmad S
Molecules; 2022 Nov; 27(22):. PubMed ID: 36432204
[TBL] [Abstract][Full Text] [Related]
7. Antiviral, virucidal and antioxidant properties of Artemisia annua against SARS-CoV-2.
Baggieri M; Gioacchini S; Borgonovo G; Catinella G; Marchi A; Picone P; Vasto S; Fioravanti R; Bucci P; Kojouri M; Giuseppetti R; D'Ugo E; Ubaldi F; Dallavalle S; Nuzzo D; Pinto A; Magurano F
Biomed Pharmacother; 2023 Dec; 168():115682. PubMed ID: 37832410
[TBL] [Abstract][Full Text] [Related]
8.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
9. Phytoconstituents of Artemisia Annua as potential inhibitors of SARS CoV2 main protease: an in silico study.
Irfan E; Dilshad E; Ahmad F; Almajhdi FN; Hussain T; Abdi G; Waheed Y
BMC Infect Dis; 2024 May; 24(1):495. PubMed ID: 38750422
[TBL] [Abstract][Full Text] [Related]
10. In Silico Screening of Natural Products as Potential Inhibitors of SARS-CoV-2 Using Molecular Docking Simulation.
Hossain R; Sarkar C; Hassan SMH; Khan RA; Arman M; Ray P; Islam MT; Daştan SD; Sharifi-Rad J; Almarhoon ZM; Martorell M; Setzer WN; Calina D
Chin J Integr Med; 2022 Mar; 28(3):249-256. PubMed ID: 34913151
[TBL] [Abstract][Full Text] [Related]
11.
Nair MS; Huang Y; Fidock DA; Polyak SJ; Wagoner J; Towler MJ; Weathers PJ
bioRxiv; 2021 Feb; ():. PubMed ID: 33442683
[TBL] [Abstract][Full Text] [Related]
12. Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies.
Azeem M; Mustafa G; Mahrosh HS
Int J Immunopathol Pharmacol; 2022; 36():3946320221142793. PubMed ID: 36442514
[TBL] [Abstract][Full Text] [Related]
13. Repurposing potential of FDA-approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
Verma AK; Aggarwal R
Chem Biol Drug Des; 2021 Apr; 97(4):836-853. PubMed ID: 33289334
[TBL] [Abstract][Full Text] [Related]
14. Coronavirus Infection-Associated Cell Death Signaling and Potential Therapeutic Targets.
Yapasert R; Khaw-On P; Banjerdpongchai R
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946543
[TBL] [Abstract][Full Text] [Related]
15. Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19.
Sehailia M; Chemat S
J Biomol Struct Dyn; 2021 Oct; 39(16):6184-6194. PubMed ID: 32696720
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
[TBL] [Abstract][Full Text] [Related]
17.
Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
[TBL] [Abstract][Full Text] [Related]
18. Natural products and phytochemicals as potential anti-SARS-CoV-2 drugs.
Merarchi M; Dudha N; Das BC; Garg M
Phytother Res; 2021 Oct; 35(10):5384-5396. PubMed ID: 34132421
[TBL] [Abstract][Full Text] [Related]
19. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
Deshpande RR; Tiwari AP; Nyayanit N; Modak M
Eur J Pharmacol; 2020 Nov; 886():173430. PubMed ID: 32758569
[TBL] [Abstract][Full Text] [Related]
20. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
